PRQR
ProQR Therapeutics·NASDAQ
--
--(--)
--
--(--)
PRQR fundamentals
During Q4 2025, ProQR Therapeutics (PRQR) reported revenue of 5.02M, a YoY change of 27.45%. Net income was -10.47M, a YoY change of -8.69%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q1,2020 | Q2,2020 | Q3,2020 | Q4,2020 | Q1,2021 | Q2,2021 | Q3,2021 | Q4,2021 | Q1,2022 | Q2,2022 | Q3,2022 | Q4,2022 | Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | Q4,2025 | TTM |
|---|
Start Date | Jan 1, 2020 | Apr 1, 2020 | Jul 1, 2020 | Oct 1, 2020 | Jan 1, 2021 | Apr 1, 2021 | Jul 1, 2021 | Oct 1, 2021 | Jan 1, 2022 | Apr 1, 2022 | Jul 1, 2022 | Oct 1, 2022 | Jan 1, 2023 | Apr 1, 2023 | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | Oct 1, 2025 | -- |
End Date | Mar 31, 2020 | Jun 30, 2020 | Sep 30, 2020 | Dec 31, 2020 | Mar 31, 2021 | Jun 30, 2021 | Sep 30, 2021 | Dec 31, 2021 | Mar 31, 2022 | Jun 30, 2022 | Sep 30, 2022 | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | 289.72K -- | 9.75M -- | 294.25K -- | 322.87K -- | 165.58K -42.85% | 774.86K -92.05% | 1.34M +355.61% | 481.01K +48.98% | 1.37M +724.72% | 1.08M +39.03% | 868.73K -35.20% | 1.30M +169.33% | 757.78K -44.51% | 1.36M +26.00% | 1.45M +66.91% | 3.54M +173.58% | 5.03M +563.60% | 6.92M +409.84% | 4.44M +205.99% | 3.94M +11.07% | 5.12M +1.79% | 4.68M -32.39% | 3.42M -22.90% | 5.02M +27.45% | 18.23M -- |
Sales and Services Revenue | -- -- | -- -- | -- -- | 0 -- | -- -- | 287.91K -- | 1.01M -- | 249.00K -- | 1.25M -- | 973.62K +238.17% | 796.34K -21.12% | 770.26K +209.34% | 712.12K -43.19% | 1.32M +35.15% | 1.45M +82.08% | 3.63M +371.63% | 4.80M +574.33% | 6.75M +413.22% | -- -- | 19.57M +438.67% | 4.88M +1.60% | 4.49M -33.48% | -- -- | 18.67M -4.61% | -- -- |
Other Revenue | 289.72K -- | 9.75M -- | 294.25K -- | -11.24M -- | 165.58K -42.85% | 486.95K -95.00% | 331.10K +12.53% | -948.45K +91.56% | 112.04K -32.33% | 103.64K -78.72% | 72.39K -78.14% | -293.13K +69.09% | 45.66K -59.24% | 41.50K -59.96% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Cost of Revenue | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Gross Profit | 289.72K -- | 9.75M -- | 294.25K -- | -11.24M -- | 165.58K -42.85% | 774.86K -92.05% | 1.34M +355.61% | -2.21M +80.33% | 1.37M +724.72% | 1.08M +39.03% | 868.73K -35.20% | -3.37M -52.36% | 757.78K -44.51% | 1.36M +26.00% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Other Operating Income | -- -- | -- -- | -- -- | 11.56M -- | -- -- | -- -- | -- -- | 1.18M -89.79% | -- -- | -- -- | -- -- | 818.40K -30.67% | -- -- | -- -- | 0 -- | 5.41M +560.83% | 226.61K -- | 167.09K -- | 153.80K -- | 140.77K -97.40% | 239.67K +5.76% | 185.97K +11.30% | 38.73K -74.82% | 32.86K -76.66% | 497.22K -- |
Operating Expenses | 18.44M -- | 13.52M -- | 13.03M -- | 14.59M -- | 14.38M -22.04% | 16.42M +21.42% | 18.19M +39.65% | 20.11M +37.85% | 20.27M +41.00% | 17.65M +7.52% | 20.26M +11.37% | 14.63M -27.29% | 10.97M -45.91% | 10.98M -37.80% | 9.27M -54.24% | 13.81M -5.58% | 13.74M +25.32% | 10.78M -1.85% | 14.15M +52.61% | 15.03M +8.87% | 16.80M +22.22% | 19.10M +77.20% | 16.66M +17.75% | 16.21M +7.83% | 68.76M -- |
Selling, General and Administrative Expenses | 4.32M -- | 3.87M -- | 3.29M -- | 4.30M -- | 3.92M -9.15% | 4.88M +26.12% | 5.32M +61.40% | 6.02M +40.08% | 5.44M +38.85% | 5.67M +16.01% | 5.24M -1.36% | 3.18M -47.16% | 4.38M -19.60% | 4.53M -20.11% | 3.51M -33.08% | 5.25M +65.26% | 3.73M -14.90% | 3.23M -28.70% | 3.66M +4.28% | 4.05M -22.92% | 3.49M -6.27% | 5.67M +75.64% | 3.66M +0.03% | 4.57M +12.74% | 17.39M -- |
General and Administrative Expenses | -- -- | -- -- | -- -- | 16.74M -- | -- -- | -- -- | -- -- | 19.66M +17.45% | -- -- | -- -- | -- -- | 19.95M +1.50% | -- -- | -- -- | 3.51M -- | 5.25M -73.67% | 3.73M -- | 3.23M -- | 3.66M +4.28% | 4.05M -22.92% | 3.49M -6.27% | 5.67M +75.64% | 3.66M +0.03% | 4.57M +12.74% | 17.39M -- |
Research and Development Expenses | 14.13M -- | 9.65M -- | 9.73M -- | 10.30M -- | 10.46M -25.98% | 11.53M +19.53% | 12.88M +32.29% | 14.10M +36.92% | 14.83M +41.80% | 11.99M +3.92% | 15.02M +16.62% | 11.45M -18.81% | 6.59M -55.57% | 6.45M -46.17% | 5.76M -61.62% | 8.55M -25.26% | 10.02M +52.04% | 7.55M +16.99% | 10.49M +82.02% | 10.98M +28.40% | 13.30M +32.81% | 13.43M +77.86% | 13.00M +23.93% | 11.64M +6.02% | 51.38M -- |
Operating Income | -18.15M -- | -3.77M -- | -12.73M -- | -14.27M -- | -14.21M +21.71% | -15.64M -314.44% | -16.85M -32.35% | -19.63M -37.60% | -18.91M -33.03% | -16.57M -5.96% | -19.39M -15.07% | -13.33M +32.11% | -10.21M +46.01% | -9.62M +41.95% | -7.82M +59.66% | -4.77M +64.23% | -8.71M +14.64% | -3.86M +59.92% | -9.71M -24.18% | -10.43M -118.86% | -11.68M -34.01% | -14.42M -273.89% | -13.24M -36.32% | -10.68M -2.31% | -50.01M -- |
Non-Operating Income (Loss) | 442.84K -- | -841.65K -- | -2.64M -- | -1.86M -- | -596.54K -234.71% | -2.96M -251.50% | -552.22K +79.08% | 11.32K +100.61% | 3.25M +645.59% | 2.48M +183.83% | -3.34M -504.46% | -898.63K -8039.85% | 580.56K -82.16% | 864.86K -65.13% | 2.04M +161.20% | -1.29M -43.78% | 453.22K -21.93% | 758.34K -12.32% | 677.62K -66.83% | 803.24K +162.17% | 795.67K +75.56% | 103.58K -86.34% | 326.23K -51.86% | 208.90K -73.99% | 1.43M -- |
Income (Loss) from Affiliates | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 581.75K -- | -- -- | -- -- | -- -- | 0 -100.00% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Income (Loss) from Associates | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Gain (Loss) on Change in Fair Value | -- -- | -- -- | -- -- | -102.73K -- | -- -- | -- -- | -- -- | -2.13M -1971.20% | -- -- | -- -- | -- -- | 2.90M +236.40% | -- -- | -- -- | -- -- | 1.05M -63.68% | -73.38K -- | 208.86K -- | 154.92K -- | 81.77K -92.24% | 304.45K +514.90% | -122.41K -158.61% | -2.35K -101.52% | 69.24K -15.32% | 248.93K -- |
Other Non-Operating Income (Loss) | -147.61K -- | -58.43K -- | -456.02K -- | 309.42K -- | -252.47K -71.04% | -39.10K +33.09% | -860.17K -88.62% | 876.01K +183.12% | 4.17M +1750.28% | 1.26M +3329.19% | -3.92M -356.18% | -2.51M -386.86% | 1.17M -71.87% | 351.62K -72.15% | 1.66M +142.27% | -3.28M -30.61% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Interest Expense | -590.46K -- | 783.22K -- | 2.18M -- | 2.07M -- | 344.07K +158.27% | 2.92M +272.74% | -307.95K -114.10% | -681.34K -132.93% | 911.84K +165.02% | -1.22M -141.71% | -586.00K -90.29% | 1.29M +289.04% | 591.44K -35.14% | -513.24K +57.85% | -384.20K +34.44% | -935.85K -172.66% | -526.60K -189.04% | -549.47K -7.06% | -522.70K -36.05% | -721.46K +22.91% | -491.22K +6.72% | -225.98K +58.87% | -328.58K +37.14% | -139.66K +80.64% | -1.19M -- |
Interest Expense | -- -- | 783.22K -- | 2.18M -- | 2.45M -- | 344.07K -- | 2.92M +272.74% | -- -- | 1.03M -57.81% | -- -- | -- -- | -- -- | 5.48M +430.21% | 591.44K -- | -- -- | -- -- | 1.61M -70.59% | -- -- | -- -- | -- -- | 1.12M -30.43% | -- -- | -- -- | -- -- | 1.51M +34.61% | -- -- |
Interest Income | 590.46K -- | -- -- | -- -- | 382.80K -- | -- -- | -- -- | 307.95K -- | 1.72M +348.23% | -- -- | 1.22M -- | 586.00K +90.29% | 4.20M +144.60% | -- -- | 513.24K -57.85% | -- -- | 2.87M -31.65% | -- -- | -- -- | -- -- | 3.37M +17.32% | -- -- | -- -- | -- -- | 2.74M -18.64% | -- -- |
Pretax Income From Continuing Operations | -17.71M -- | -4.62M -- | -15.37M -- | -16.13M -- | -14.81M +16.39% | -18.60M -302.96% | -17.40M -13.21% | -19.62M -21.64% | -15.65M -5.69% | -14.09M +24.23% | -22.73M -30.60% | -14.23M +27.49% | -9.63M +38.49% | -8.76M +37.87% | -5.78M +74.57% | -6.06M +57.41% | -8.26M +14.20% | -3.10M +64.63% | -9.04M -56.34% | -9.63M -58.94% | -10.88M -31.73% | -14.31M -362.08% | -12.92M -42.93% | -10.47M -8.68% | -48.58M -- |
Income Tax Expense | -- -- | 12.36K -- | 87.92K -- | 46.47K -- | 8.22K -- | 62.79K +408.02% | 40.52K -53.91% | 24.90K -46.42% | 7.77K -5.54% | 20.94K -66.66% | 67.50K +66.59% | -- -- | -- -- | -45.86K -319.05% | -43.39K -164.29% | 5.53K -- | 3.24K -- | -214.22K -367.08% | -- -- | -- -- | -- -- | 21.19K +109.89% | -- -- | 1.17K -- | -- -- |
Net Income | -17.71M -- | -4.63M -- | -15.46M -- | -16.18M -- | -14.82M +16.34% | -18.66M -303.24% | -17.45M -12.83% | -19.65M -21.44% | -15.66M -5.69% | -14.12M +24.37% | -22.80M -30.68% | -14.23M +27.58% | -9.63M +38.52% | -8.71M +38.29% | -5.74M +74.84% | -6.07M +57.37% | -8.26M +14.16% | -2.88M +66.90% | -9.04M -57.52% | -9.63M -58.80% | -10.88M -31.67% | -14.33M -397.14% | -12.92M -42.93% | -10.47M -8.69% | -48.60M -- |
Net Income Attributable to Minority Interests | -25.34K -- | -7.87K -- | -9.38K -- | -13.45K -- | -12.92K +49.02% | -8.29K -5.44% | -25.47K -171.58% | -21.50K -59.85% | -8.87K +31.30% | 227.18K +2839.19% | 13.70K +153.78% | -3.21K +85.08% | 84.80K +1055.58% | 17.47K -92.31% | 306.94K +2141.03% | 0 +100.00% | 0 -100.00% | 0 -100.00% | -- -- | 0 -- | 0 -- | 0 -- | -- -- | 0 -- | -- -- |
Net Income Attributable to Owners of the Company | -17.69M -- | -4.62M -- | -15.45M -- | -16.16M -- | -14.80M +16.29% | -18.66M -303.75% | -17.42M -12.74% | -19.63M -21.41% | -15.65M -5.72% | -14.34M +23.12% | -22.81M -30.95% | -14.23M +27.52% | -9.71M +37.95% | -8.73M +39.14% | -6.04M +73.51% | -6.07M +57.36% | -8.26M +14.91% | -2.88M +66.97% | -9.04M -49.52% | -9.63M -58.80% | -10.88M -31.67% | -14.33M -397.14% | -12.92M -42.93% | -10.47M -8.69% | -48.60M -- |
Net Income Attributable to Common Stockholders | -17.69M -- | -4.62M -- | -15.45M -- | -16.16M -- | -14.80M +16.29% | -18.66M -303.75% | -17.42M -12.74% | -19.63M -21.41% | -15.65M -5.72% | -14.34M +23.12% | -22.81M -30.95% | -14.23M +27.52% | -9.71M +37.95% | -8.73M +39.14% | -6.04M +73.51% | -6.07M +57.36% | -8.26M +14.91% | -2.88M +66.97% | -9.04M -49.52% | -9.63M -58.80% | -10.88M -31.67% | -14.33M -397.14% | -12.92M -42.93% | -10.47M -8.69% | -48.60M -- |
Other Comprehensive Income | 282.01K -- | -151.70K -- | -298.94K -- | -251.94K -- | 465.02K +64.90% | -167.06K -10.12% | 238.49K +179.78% | 178.82K +170.98% | 246.26K -47.04% | 721.31K +531.78% | 598.72K +151.05% | -792.72K -543.30% | -238.10K -196.68% | 7.64K -98.94% | -354.56K -159.22% | -518.81K +34.55% | 206.11K +186.56% | 91.04K +1091.05% | -420.17K -18.50% | 656.25K +226.49% | -400.53K -294.33% | -802.71K -981.68% | -26.99K +93.58% | -10.56K -101.61% | -1.24M -- |
Total Comprehensive Income | -17.43M -- | -4.78M -- | -15.76M -- | -16.43M -- | -14.35M +17.66% | -18.83M -293.94% | -17.21M -9.18% | -19.47M -18.49% | -15.41M -7.40% | -13.39M +28.87% | -22.20M -29.02% | -15.02M +22.84% | -9.87M +36.00% | -8.70M +35.02% | -6.09M +72.56% | -6.58M +56.17% | -8.06M +18.32% | -2.79M +67.92% | -9.46M -55.25% | -8.98M -36.32% | -11.28M -40.01% | -15.14M -442.10% | -12.94M -36.86% | -10.48M -16.75% | -49.84M -- |
Total Comprehensive Income Attributable to Minority Interests | -25.34K -- | -7.87K -- | -9.38K -- | -13.45K -- | -12.92K +49.02% | -8.29K -5.44% | -25.47K -171.58% | -21.50K -59.85% | -8.87K +31.30% | 227.18K +2839.19% | 13.70K +153.78% | -3.21K +85.08% | 84.80K +1055.58% | 17.47K -92.31% | 306.94K +2141.03% | 0 +100.00% | 0 -100.00% | 0 -100.00% | -- -- | 0 -- | 0 -- | 0 -- | -- -- | 0 -- | -- -- |
Total Comprehensive Income Attributable to Owners of the Company | -17.40M -- | -4.77M -- | -15.75M -- | -16.42M -- | -14.34M +17.61% | -18.82M -294.42% | -17.18M -9.08% | -19.45M -18.46% | -15.40M -7.43% | -13.62M +27.63% | -22.21M -29.29% | -15.02M +22.77% | -9.95M +35.41% | -8.72M +35.98% | -6.40M +71.20% | -6.58M +56.16% | -8.06M +19.02% | -2.79M +67.98% | -9.46M -47.80% | -8.98M -36.32% | -11.28M -40.01% | -15.14M -442.10% | -12.94M -36.86% | -10.48M -16.75% | -49.84M -- |
Basic EPS | -0.35 -- | -0.09 -- | -0.3 -- | -0.32 -- | -0.29 +17.14% | -0.28 -211.11% | -0.25 +16.67% | -0.29 +9.38% | -0.22 +24.14% | -0.2 +28.57% | -0.32 -28.00% | -0.18 +37.93% | -0.12 +45.45% | -0.11 +45.00% | -0.07 +78.13% | -0.07 +61.11% | -0.1 +16.67% | -0.03 +72.73% | -0.11 -57.14% | -0.09 -28.57% | -0.11 -10.00% | -0.14 -366.67% | -0.12 -9.09% | -0.1 -11.11% | -0.47 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.07 -- | -- -- | -0.1 -- | -0.03 -- | -0.11 -57.14% | -- -- | -0.11 -10.00% | -0.14 -366.67% | -0.12 -9.09% | -- -- | -- -- |
Diluted EPS | -0.35 -- | -0.09 -- | -0.3 -- | -- -- | -0.29 +17.14% | -0.28 -211.11% | -0.25 +16.67% | -- -- | -0.22 +24.14% | -0.2 +28.57% | -0.32 -28.00% | -- -- | -0.12 +45.45% | -0.11 +45.00% | -0.07 +78.13% | -- -- | -0.1 +16.67% | -0.03 +72.73% | -0.11 -57.14% | -- -- | -0.11 -10.00% | -0.14 -366.67% | -0.12 -9.09% | -- -- | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.07 -- | -- -- | -0.1 -- | -0.03 -- | -0.11 -57.14% | -- -- | -0.11 -10.00% | -0.14 -366.67% | -0.12 -9.09% | -- -- | -- -- |
You can ask Aime
What factors drove the changes in ProQR Therapeutics's revenue and profit?What does ProQR Therapeutics do and what are its main business segments?What is ProQR Therapeutics's latest dividend and current dividend yield?What guidance did ProQR Therapeutics's management provide for the next earnings period?What were the key takeaways from ProQR Therapeutics’s earnings call?What is ProQR Therapeutics's gross profit margin?What is the market's earnings forecast for ProQR Therapeutics next quarter?Did ProQR Therapeutics beat or miss consensus estimates last quarter?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
